Giovanni Ciancio1, Manuela Ferracin2, Elena Saccenti3, Valentina Bagnari4, Ilaria Farina4, Federica Furini4, Elisa Galuppi4, Barbara Zagatti3, Francesco Trotta4, Massimo Negrini3, Marcello Govoni4. 1. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Sant'Anna University Hospital, Ferrara, Italy. g.ciancio@ospfe.it. 2. Department of Experimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna, Italy. 3. Department of Morphology, Surgery and Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Italy. 4. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Sant'Anna University Hospital, Ferrara, Italy.
Abstract
OBJECTIVES: To evaluate the micro-RNA (miRNA) expression profile in patients with early psoriatic arthritis (PsA) in order to assess the role of miRNAs as potential PsA biomarkers. METHODS: The expression of 723 mature miRNAs in peripheral blood mononuclear cells of early PsA patients in comparison with early-rheumatoid arthritis (ERA) patients and healthy controls (HC) was evaluated using a miRNA microarray. All patients had active disease and were naïve from treatment. The results were validated for a specific miRNA (miR-21-5p) in the entire series of patients plus an additional group of early PsA, ERA and HC using droplet digital PCR. RESULTS: In PsA, microarray analysis revealed a distinct pattern of 19 (vs. HC) and 48 (vs. ERA) deregulated miRNAs (p<0.05). The significant up-regulation of miR-21-5p both in early PsA and in ERA in comparison with HC was validated and confirmed. In PsA, miR-21-5p was found significantly down regulated after 12 weeks of therapy, which significantly correlated with the reduction of DAPSA score. CONCLUSIONS: In early PsA, a 19- (vs. HC) and 48- (vs. ERA) miRNA signature was identified. A differential expression of miRNAs in patients with active disease makes them attractive biomarkers of psoriatic disease. MiR-21-5p was found up-regulated both in early PsA and ERA, a finding which highlights its role in the inflammatory process in general and its potential role as a therapeutic target in different inflammatory disorders. A potential role of miR-21-5p as a response to treatment biomarker in early PsA has been identified.
OBJECTIVES: To evaluate the micro-RNA (miRNA) expression profile in patients with early psoriatic arthritis (PsA) in order to assess the role of miRNAs as potential PsA biomarkers. METHODS: The expression of 723 mature miRNAs in peripheral blood mononuclear cells of early PsA patients in comparison with early-rheumatoid arthritis (ERA) patients and healthy controls (HC) was evaluated using a miRNA microarray. All patients had active disease and were naïve from treatment. The results were validated for a specific miRNA (miR-21-5p) in the entire series of patients plus an additional group of early PsA, ERA and HC using droplet digital PCR. RESULTS: In PsA, microarray analysis revealed a distinct pattern of 19 (vs. HC) and 48 (vs. ERA) deregulated miRNAs (p<0.05). The significant up-regulation of miR-21-5p both in early PsA and in ERA in comparison with HC was validated and confirmed. In PsA, miR-21-5p was found significantly down regulated after 12 weeks of therapy, which significantly correlated with the reduction of DAPSA score. CONCLUSIONS: In early PsA, a 19- (vs. HC) and 48- (vs. ERA) miRNA signature was identified. A differential expression of miRNAs in patients with active disease makes them attractive biomarkers of psoriatic disease. MiR-21-5p was found up-regulated both in early PsA and ERA, a finding which highlights its role in the inflammatory process in general and its potential role as a therapeutic target in different inflammatory disorders. A potential role of miR-21-5p as a response to treatment biomarker in early PsA has been identified.
Authors: Andrea Pelosi; Claudio Lunardi; Piera Filomena Fiore; Elisa Tinazzi; Giuseppe Patuzzo; Giuseppe Argentino; Francesca Moretta; Antonio Puccetti; Marzia Dolcino Journal: Biomed Res Int Date: 2018-04-23 Impact factor: 3.411
Authors: Sarah M Wade; Nils Ohnesorge; Hayley McLoughlin; Monika Biniecka; Steven P Carter; Michelle Trenkman; Clare C Cunningham; Trudy McGarry; Mary Canavan; Breandán N Kennedy; Douglas J Veale; Ursula Fearon Journal: EBioMedicine Date: 2019-08-26 Impact factor: 8.143
Authors: Francesca Motta; Andrea Pederzani; Maria Cristina Carena; Angela Ceribelli; Paul B Wordsworth; Maria De Santis; Carlo Selmi; Matteo Vecellio Journal: Curr Rheumatol Rep Date: 2021-07-03 Impact factor: 4.592